# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and lowers the price target from $65 to...
Gold prices declined 2.7% in NY due to reduced geopolitical risks. Silver also fell 5.1%. Israeli officials averted a US-backed...
Deutsche Bank analyst Justin Bowers maintains 10x Genomics (NASDAQ:TXG) with a Buy and lowers the price target from $60 to $55.
Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and lowers the price target from $55 to ...
On Thursday, Cathie Wood-led Ark Invest made a significant move by selling shares of Coinbase Global Inc (NASDAQ:COIN), despite...
The next generation of the company's leading single cell technology architecture, GEM-X, enables higher performance at larg...
Gold prices surge on record close and mining stock rally. GLD reaches $2,110/oz, within 1.4% of all-time high.